BioCentury
ARTICLE | Company News

BioXell, Novo Nordisk deal

January 4, 2010 8:00 AM UTC

BioXell sold Novo Nordisk its triggering receptors expressed on myeloid cells (TREM) 1 program for €1 million ($1.4 million). The deal includes compounds targeting TREM1 and research tools. BioXell is...